Research At a Glance
- Research Category
- Metabolic & Incretin Signaling Research
- Peptide Length
- 39 amino acids (dual GIP/GLP-1 agonist, acylated)
- Purity
- ≥ 99% (HPLC)
- Published Studies
- 2,300+ indexed
- Storage
- Lyophilized: −20 °C long term, 2–8 °C short term. Reconstituted: 2–8 °C, use within 30 days.
Published-study figures are approximate PubMed result counts and indicate the volume of available literature only. Purity reflects third-party analytical testing on the corresponding lot; see the Quality Assurance Center for lot-matched certificates.
What Is GLP-2 (Tirzepatide)?
GLP-2 is a synthetic peptide studied as a dual receptor agonist, engaging both the GLP-1 and GIP receptor pathways. In the scientific literature, this compound is referred to by its generic name, tirzepatide, and has been the subject of extensive receptor-signaling and metabolic pathway research due to its dual-mechanism profile.
Note: Tirzepatide has received regulatory approval in some jurisdictions under specific brand names for prescription use. Queen BioLabs supplies this compound strictly for laboratory and analytical research purposes; it is not sold, marketed, or intended for human or veterinary use, consumption, or administration in any form.
Why Researchers Study It
The dual GLP-1/GIP receptor mechanism makes this compound a reference point for laboratory investigation into:
- Comparative receptor pharmacology — how simultaneous GLP-1 and GIP receptor activation differs mechanistically from single-target incretin research models
- Dose-response and receptor-binding studies — structure-activity relationships across the GIP and GLP-1 receptor families
- Comparative peptide research — used as a benchmark compound against both single-agonist and triple-agonist molecules in receptor-pathway literature
What the Published Literature Shows
Tirzepatide’s receptor mechanism and metabolic pathway effects have been characterized across a series of randomized, controlled Phase 3 trials (the SURMOUNT program), published in peer-reviewed journals including the New England Journal of Medicine. These trials, conducted in adult populations with obesity, examined dose-dependent effects of the compound across multiple maintenance dose levels compared with placebo, and later trials compared it directly against single-receptor GLP-1 agonist compounds.
Across this trial program, researchers observed that higher maintenance doses were associated with progressively greater effects on body weight compared to placebo, with the majority of participants at higher doses meeting the study’s response thresholds. The most frequently reported adverse events were gastrointestinal in nature, consistent with the broader incretin-receptor-agonist class, and typically occurred during dose escalation. A head-to-head trial comparing this compound to a single-receptor GLP-1 agonist found a greater magnitude of effect for the dual-agonist compound, which researchers have attributed to the non-overlapping central expression patterns of GIP and GLP-1 receptors.
This body of literature is frequently referenced by researchers designing comparative studies on single- versus dual- versus triple-receptor incretin pathway agonism.
Sources
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. View on NEJM
Garvey WT, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2024. View on NEJM
Compound Specifications
| Classification | Synthetic peptide, dual receptor agonist |
|---|---|
| Molecular target | GLP-1R, GIPR |
| Format | Lyophilized powder |
| Purity | ≥99% (HPLC-verified per lot) |
| Storage | −20°C; refrigerate 2–8°C after laboratory handling |
| Development code | LY3298176 |
Certificate of Analysis
Every lot is independently tested and lot-matched. View Certificates of Analysis